ATHE 6-K
Alterity Therapeutics Ltd (ATHE)
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM6-K
REPORTOF FOREIGN PRIVATE ISSUER
PURSUANTTO RULE 13a-16 OR 15d-163
UNDERTHE SECURITIES EXCHANGE ACT OF 1934
Forthe month of April 2025
AlterityTherapeutics Limited
(Name of Registrant)
Level 14, 350 Collins Street,Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicateby check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
ThisForm 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980and 333-228671) and ourRegistration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417and 333-250076)
ALTERITYTHERAPEUTICS LIMITED
(adevelopment stage enterprise)
The following exhibits are submitted:
| 99.1 | Application for quotation of securities - ATH |
|---|
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alterity Therapeutics Limited | |
|---|---|
| By: | /s/ Geoffrey P. Kempler |
| Geoffrey P. Kempler | |
| Chairman |
Date: April 22, 2025
2
Exhibit 99.1
![]() |
Appendix 2A - Application for quotation of securities |
|---|
Announcement Summary
Entity name
ALTERITY THERAPEUTICS LIMITED
Announcement Type
New announcement
Date of this announcement
Tuesday April 22, 2025
The+securities to be quoted are:
Other
Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.
| New class of options as announced in Appendix 3Bs dated 10/02/2025<br>and 24/02/2025. |
|---|
Total number of +securities to be quoted
| **** | ASX +security code | Security description | Number of +securities to be quoted | Issue date |
|---|---|---|---|---|
| New class - code to be confirmed | Options with exercise price of $0.028, expiring 26 February 2027 | 1,222,300,911 | 23/04/2025 |
Refer to next page for full details of the announcement
| Appendix 2A - Application for quotation of securities | 1 / 7 |
| --- | --- |
|
| Appendix 2A - Application for quotation of securities |
| --- | --- |
Part 1 - Entity and announcement details
1.1Name of entity
ALTERITY THERAPEUTICS LIMITED
We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.
| **** | 1.2 Registered number type | Registration number |
|---|---|---|
| ABN | 37080699065 |
1.3ASX issuer code
ATH
1.4The announcement is
New announcement
1.5Date of this announcement
22/4/2025
| Appendix 2A - Application for quotation of securities | 2 / 7 |
| --- | --- |
|
| Appendix 2A - Application for quotation of securities |
| --- | --- |
Part 2 - Type of Issue
2.1 The+securities to be quoted are:
Other
Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.
2.2 The +class of +securities to be quoted is:
New +securities in a class that is not yet quoted on ASX (“new class”)
2.3c Have these+securities been offered under a +disclosure document or +PDS?
Yes
2.3c.1 Dateof +disclosure document or +PDS?
17/4/2025
2.3d Pleaseprovide any further information needed to understand the circumstances in which you are applying to have these +securities quoted onASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B
| New class<br>of options as announced in Appendix 3Bs dated 10/02/2025 and 24/02/2025. |
|---|
| Appendix 2A - Application for quotation of securities | 3 / 7 |
| --- | --- |
|
| Appendix 2A - Application for quotation of securities |
| --- | --- |
Part 3C - number and type of +securities to be quoted (new class) where issue has not previously been notified to ASX in an Appendix 3B
New +securities
| ASX +security code | +Security description |
|---|---|
| New class - code to be confirmed | Options with exercise price of $0.028, expiring 26 February 2027 |
| +Security type | ISIN code |
| Options |
Issue date
23/4/2025
Will all the +securities issued in this class rank equally in all respects from the issue date?
Yes
Options Details
| +Security currency | Exercise price | Expiry date |
|---|---|---|
| AUD - Australian Dollar | AUD 0.02800000 | 26/2/2027 |
Details of the type of +security that will be issued if an option is exercised
ATH : ORDINARY FULLY PAID
Number of +securities that will be issued if an option is exercised
| 1,222,300,911 |
|---|
Please provide a URL link for a document lodged with ASX setting out the materialterms of the +securities to be quoted or provide the information by separate announcement.
| Provided in Options Prospectus announcement on 17 April 2025. |
|---|
| Appendix 2A - Application for quotation of securities | 4 / 7 |
| --- | --- |
|
| Appendix 2A - Application for quotation of securities |
| --- | --- |
Issue details
Number of +securities to be quoted
1,222,300,911
Are the +securities being issued for a cash consideration?
No
Pleasedescribe the consideration being provided for the +securities
| Nil consideration. |
|---|
Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the
+securities to be quoted
0.000001
Any other information the entity wishes to provide about the +securities to be quoted
The purpose(s) for which the entity is issuing the securities
To raise additional working capital
| Appendix 2A - Application for quotation of securities | 5 / 7 |
| --- | --- |
|
| Appendix 2A - Application for quotation of securities |
| --- | --- |
Part 4 - Issued capital following quotation
Following thequotation of the +securities the subject of this application, the issued capital of the entity will comprise:
The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity’s current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.
4.1 Quoted +securities(total number of each +class of +securities quoted on ASX following the +quotation of the+securities subject of this application)
| ASX +security code and description | Total number of +securities on issue | **** | |
|---|---|---|---|
| ATH : ORDINARY FULLY PAID | 9,127,370,686 | ||
| ATHO : OPTION EXPIRING 31-AUG-2026 | 932,611,269 | ||
| New class - code to be confirmed : Options with exercise price of 0.028, expiring 26 February 2027 | 1,222,300,911 |
All values are in US Dollars.
4.2 Unquoted+securities (total number of each +class of +securities issued but not quoted on ASX)
| ASX +security code and description | Total number of<br> <br>+securities on issue | |
|---|---|---|
| ATHAAE : OPTION EXPIRING 29-NOV-2026 EX 0.0375 | 14,250,000 | |
| ATHAAG : OPTION EXPIRING 29-NOV-2026 EX 0.0238 | 11,900,000 | |
| ATHAAB : OPTION EXPIRING 17-SEP-2025 EX 0.09 | 35,000,000 | |
| ATHAAK : OPTION EXPIRING 30-DEC-2027 EX 0.01 | 170,000,000 | |
| ATHAAH : OPTION EXPIRING 19-DEC-2026 EX 0.0105 | 8,000,000 | |
| ATHAB : OPTION EXPIRING 13-MAR-2029 EX US0.0031 | 62,500,000 | |
| ATHAA : OPTION EXPIRING 13-MAR-2029 EX 0.004 | 20,166,667 | |
| ATHAC : OPTION EXPIRING 21-MAR-2029 EX US0.003 | 120,000,000 | |
| ATHAAD : OPTION EXPIRING 06-JAN-2026 EX 0.032 | 91,392,720 |
All values are in US Dollars.
| Appendix 2A - Application for quotation of securities | 6 / 7 |
| --- | --- |
|
| Appendix 2A - Application for quotation of securities |
| --- | --- |
Part 5 - Other Listing Rule requirements
5.1 Are the +securities being issued under an exceptionin Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?
No
5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?
Yes
5.2a Date of meeting or proposed meeting to approve the issue under listing rule 7.1
31/3/2025
| Appendix 2A - Application for quotation of securities | 7 / 7 |
|---|